CBD Global Sciences Ret. on equity
What is the Ret. on equity of CBD Global Sciences?
The Ret. on equity of CBD Global Sciences Inc. is 67.40%
What is the definition of Ret. on equity?
Return on equity is a measure of the profitability of a business in relation to the book value of the shareholder equity. It is computed by dividing fiscal year net income by total shareholder equity.
ttm (trailing twelve months)
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
Ret. on equity of companies in the Health Care sector on OTC compared to CBD Global Sciences
What does CBD Global Sciences do?
CBD Global Sciences Inc. engages in cannabidiol (CBD) farming, processing, and product manufacturing business. It offers provides biomass, CBD oil, and CBD oil products under the Aethics, CannaOil, and Strasburg Pharms brand names. The company was incorporated in 2018 and is headquartered in Lakewood, Colorado.
Companies with ret. on equity similar to CBD Global Sciences
- Q BioMed has Ret. on equity of 66.88%
- Karyopharm Therapeutics Inc has Ret. on equity of 66.89%
- RattanIndia Infrastructure has Ret. on equity of 66.93%
- InterGlobe Aviation has Ret. on equity of 67.04%
- MediaAlpha has Ret. on equity of 67.20%
- Pool Dl ,001 has Ret. on equity of 67.23%
- CBD Global Sciences has Ret. on equity of 67.40%
- Genfit SA has Ret. on equity of 67.45%
- Okura has Ret. on equity of 67.68%
- Lazard Ltd has Ret. on equity of 67.78%
- PayPoint Plc has Ret. on equity of 67.83%
- C4X Discovery Plc has Ret. on equity of 67.84%
- Pressure BioSciences has Ret. on equity of 67.92%